Table 1.
Phase 2 and 3 clinical trials based on the CAR-T cell therapy in the context of the tumor immunotherapy registered in ClinicalTrials.gov (June 2021)
| Condition | Target antigen | Phase | Participant Number | Location | Status | NCT number |
|---|---|---|---|---|---|---|
| Lymphoma | CD19 | 2 | 78 | France | Recruiting | NCT04703686 |
| MM | BCMA | 2 | 60 | China | Active, not recruiting | NCT03758417 |
| AML | CD123 | 2/3 | 20 | China | Recruiting | NCT03631576 |
| B-ALL | CD19 | 2/3 | 10 | Malaysia | Recruiting | NCT03937544 |
| B cell leukemia/lymphoma | CD19 | 2 | 25 | Sweden | Active, not recruiting | NCT03068416 |
| B-ALL | CD19,CD22 | 1/2 | 20 | China | Recruiting | NCT04723901 |
| B cell lymphoma | CD19,CD20 | 1/2 | 20 | China | Recruiting | NCT04723914 |
| Leukemia or lymphoma | CD19 | 1/2 | 16 | USA | Active, not recruiting | NCT03684889 |
| NHL | CD19,CD20 | 1/2 | 30 | China | Recruiting | NCT04697940 |
| Gastric and pancreatic cancers | Claudin | 1/2 | 102 | China | Recruiting | NCT04581473 |
| NSCLC | MUC1 | 1/2 | 60 | China | Recruiting | NCT03525782 |
| AML | CLL1,CD33,CD123 | 1/2 | 10 | China | Recruiting | NCT04010877 |
| MM | SLAMF7 | 1/2 | 38 | Germany | Recruiting | NCT04499339 |
| B cell lymphoma | CD19 | 1/2 | 11 | China | Recruiting | NCT04429438 |
| B-ALL | CD19 | 1/2 | 185 | Germany | Recruiting | NCT04404660 |
| Ovarian cancer | MESO | 1/2 | 20 | China | Recruiting | NCT03916679 |
| AML and MM | CD44v6 | 1/2 | 58 | Italy | Recruiting | NCT04097301 |
| Sarcoma | CD133, GD2, MUC1, CD11 | 1/2 | 20 | China | Recruiting | NCT03356782 |
| B-ALL | CD19 | 1/2 | 15 | Sweden | Completed | NCT02132624 |
| MM | CD38 , BCMA | 1/2 | 80 | China | Recruiting | NCT03767751 |
| B-All | CD19 , CD22 | 1/2 | 23 | UK | Completed | NCT03289455 |
| MM | BCMA | 1/2 | 220 | USA | Recruiting | NCT03288493 |
| MCL | CD19 | 2 | 59 | China | Recruiting | NCT04718883 |
| AML | CD33, CD123,CLL-1 | 1/2 | 10 | China | Recruiting | NCT04010877 |
| B-ALL and B-NHL | CD19 | 2 | 90 | USA | Recruiting | NCT04148430 |
| MCL | CD19 | 2 | 36 | USA | Recruiting | NCT04484012 |
| HL | CD30 | 2 | 94 | USA | Recruiting | NCT04268706 |
| ALL and NHL | CD19 | 1/2 | 32 | Italy | Recruiting | NCT03373071 |
| Neuroblastoma | GD2 | 1/2 | 42 | Italy | Recruiting | NCT03373097 |
| HL | CD30 | 1/2 | 30 | Spain | Recruiting | NCT04653649 |
| Solid tumors | PSMA | 1/2 | 100 | China | Recruiting | NCT04429451 |
| B cell lymphoma | CD19 | 1/2 | 43 | USA | Active, not recruiting | NCT00924326 |
| ALL and NHL | CD19 | 1/2 | 24 | Turkey | Recruiting | NCT04206943 |
| B cell lymphoma | CD19 | 1/2 | 20 | USA | Recruiting | NCT04257578 |
| B cell lymphoma | CD19 | 1/2 | 1 | USA | Completed | NCT01475058 |
| Solid tumors | Mesothelin | 1/2 | 15 | USA | Terminated | NCT01583686 |
| Melanoma and renal cancers | VEGFR2 | 1/2 | 24 | USA | Terminated | NCT01218867 |
| NHL | CD19,CD20 | 1/2 | 80 | China | Recruiting | NCT04553393 |
| Pancreatic and prostate cancer | PSCA | 1/2 | 151 | USA | Recruiting | NCT02744287 |
| Leukemia | CD19 | 1/2 | 177 | China | Completed | NCT03173417 |
| ALL | CD22 | 2 | 100 | China | Recruiting | NCT04340167 |
| B cell leukemia or lymphoma | CD19, CD20 | 1/2 | 100 | China | Completed | NCT03097770 |
| Esophageal cancer | PD1, MUC1 | 1/2 | 20 | China | Recruiting | NCT03706326 |
|
NHL MCL |
CD19, CD20 | 1/2 | 32 | USA | Recruiting | NCT04186520 |
| B cell leukemia/ lymphoma | CD19, CD22 | 1/2 | 40 | China | Recruiting | NCT04648475 |
| B cell leukemia/ lymphoma | CD22 | 1/2 | 42 | USA | Recruiting | NCT04571138 |
| Acute leukemia | CD19 | 1/2 | 167 | USA | Active, not recruiting | NCT02028455 |
| B-ALL | CD19 | 1/2 | 18 | Russian | Active, not recruiting | NCT03467256 |
| B-ALL and B-NHL | CD19 | 1/2 | 50 | USA | Recruiting | NCT04544592 |
| ALL and NHL | CD19 | 1/2 | 60 | Canada | Recruiting | NCT03765177 |
| MM | BCMA | 1/2 | 30 | USA | Recruiting | NCT03448978 |
| ALL | CD19 | 1/2 | 35 | USA | Recruiting | NCT03573700 |
| Pancreatic and prostate cancer | PSCA | 1/2 | 151 | USA | Recruiting | NCT02744287 |
| B cell leukemia/ lymphoma | CD19,CD22 | 1/2 | 30 | USA | Not yet recruiting | NCT04029038 |
| B cell leukemia/ lymphoma | CD19,CD22 | 1/2 | 40 | China | Recruiting | NCT04649983 |
| Acute leukemia | CD19, BCMA | 1/2 | 20 | China | Recruiting | NCT04846439 |
| Brain tumors | EGFRvIII | 1/2 | 18 | USA | Completed | NCT01454596 |
| ALL and NHL | CD19 | 1/2 | 24 | Turkey | Recruiting | NCT04206943 |
| B cell malignancies | CD19, CD20, CD22 CD30, CD38, CD70, CD123 | 1/2 | 100 | China | Recruiting | NCT03125577 |
| B-ALL | CD19 | 2 | 82 | USA | Terminated | NCT02535364 |
| DLBCL | CD19 | 2 | 115 | USA | Active, not recruiting | NCT02445248 |
| Adult large B cell lymphoma | CD19 | 1/2 | 91 | South Korea | Recruiting | NCT04836507 |
| DLBCL | CD19 | 2 | 25 | USA | Terminated | NCT03954106 |
| Solid tumors | NY-ESO-1 | 1/2 | 50 | China | Recruiting | NCT03941626 |
| B- ALL and B-NHL | CD19 | 1/2 | 300 | Israel | Recruiting | NCT02772198 |
| ALL, DLBCL and PML | CD19 | 1/2 | 32 | Italy | Recruiting | NCT04787263 |
| B cell lymphoma | CD19 | 4 | 10 | China | Not yet recruiting | NCT02992834 |
| NHL and ALL | CD19 | 1/2 | 63 | Canada | Recruiting | NCT03938987 |
| AML | CD33 | 1/2 | 34 | USA | Recruiting | NCT03971799 |
| ALL, NHL, CLL, DLBCL, FL MCL | CD19 | 1/2 | 48 | Germany | Recruiting | NCT03676504 |
| Glioblastoma | B7-H3 (CD276) | 1/2 | 40 | China | Recruiting | NCT04077866 |
| AML and CLL | CD19 | 1/2 | 28 | China | Completed | NCT03076437 |
| MM | BCMA | 2 | 120 | USA | Recruiting | NCT04133636 |
| DLBCL, FL and MCL | CD19 | 1/2 | 12 | USA | Active, not recruiting | NCT02650999 |
| B cell malignancy | CD19,CD20 | 1/2 | 100 | China | Completed | NCT03097770 |
| T-ALL, T-NHL and AML | CD7 | 1/2 | 108 | China | Recruiting | NCT04599556 |
| Esophageal cancer | MUC1,PD-1 | 1/2 | 20 | China | Recruiting | NCT03706326 |
| NHL and MCL | CD19,CD20 | 1/2 | 32 | USA | Recruiting | NCT04186520 |
| Leukemia/lymphoma | CD22 | 1/2 | 42 | USA | Recruiting | NCT04571138 |
| Cervical cancer | GD2, PSMA, MUC1, Mesothelin | 1/2 | 20 | China | Recruiting | NCT03356795 |
| Acute leukemia | CD19 | 1/2 | 167 | USA | Active, not recruiting | NCT02028455 |
| B-ALL | CD19 | 1/2 | 18 | Russian | Active, not recruiting | NCT03467256 |
| B-ALL and B-NHL | CD19 | 1/2 | 50 | USA | Recruiting | NCT04544592 |
| ALL and NHL | CD19 | 1/2 | 60 | Canada | Recruiting | NCT03765177 |
| HL and NHL | CD30 | 1/2 | 40 | USA | Recruiting | NCT02690545 |
| MM | BCMA | 1/2 | 30 | USA | Recruiting | NCT03448978 |
| T cell lymphoma | CD30 | 2 | 20 | USA | Recruiting | NCT04083495 |
| Solid tumors | Mesothelin | 1/2 | 179 | USA | Recruiting | NCT02414269 |
| B- NHL | CD19 | 2 | 61 | USA | Active, not recruiting | NCT03483103 |
Note: ALL acute lymphoblastic leukemia, NHL non-Hodgkin’s lymphoma, AML acute myeloid leukemia, HL Hodgkin lymphoma, BCMA B cell maturation antigen, MM multiple myeloma, MCL mantle cell lymphoma, DLBCL diffuse large B cell lymphoma, CLL chronic lymphocytic leukemia, FL follicular lymphoma, PSMA prostate-specific membrane antigen, PSCA prostate stem cell antigen, SLAMF7 signaling lymphocytic activation molecule F7